Immuno-dominant peptides might be considered for immunomodulation therapy, particularly in autoimmune myocarditis because there is an opportunity to treat DR4 positive acute myocarditis patients before the development of chronic myocarditis or DCM. Here, TNFRSF10A is linked to familial dilated cardiomyopathy.